Physicians' Academy for Cardiovascular Education
Also as CME accredited e-learning

The CANTOS trial: Implications for the management of patients with residual risk

10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME

Anti-inflammatory therapy in the prevention of cardiovascular disease

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA

No evidence that anti-inflammatory treatment prevents progression to T2DM in CANTOS trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Brendan Everett, MD - Boston, MA, USA

Anti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Paul Ridker - Boston, MA, USA
Also as CME e-learning

Inflammation & CVD: Translating insights from vascular biology to the clinic

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA - Online CME
Also as CME accredited e-learning

The new era of residual risk reduction

10' education - Nov. 16, 2017 - Prof. Erik Stroes - Amsterdam, The Netherlands - Online CME

The patient with inflammatory residual risk: Who is it?

10' education - Nov. 16, 2017 - Prof. Wolfgang Koenig - Munich, Germany - Online CME

There is hope for treatment of HFpEF

3' education - Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore

Analogous to LDL-c, the lower the better also seems true for inflammation

3' education - Nov. 14, 2017 - Paul Ridker, Boston, MA, USA

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

10' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain

A new challenge for precision medicine: selecting major contributing risk factors

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazione

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain

After 23 years, CANTOS trial shows that inflammatory hypothesis is right

10' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain

L’inflammation est critique dans la prévention secondaire des évènements cardiovasculaires

5' education - Aug. 28, 2017 - ESC 2017, Barcelona, Spain

Anti-inflammatory therapy that does not affect thrombosis or LDL-c, can beneficially impact arterial disease

5' education - Aug. 28, 2017 - ESC 2017, Barcelona, Spain

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

10' education - Aug. 28, 2017

Decades of science on the inflammatory hypothesis of atherosclerosis translate into actionable clinical therapeutic to reduce residual CV risk

3' education - Aug. 27, 2017

Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients

3' education - Aug. 27, 2017

HIV as a model to study effect of chronic inflammation on CV risk

3' education - Mar. 16, 2017 - VBWG ACC 2017

Lowering inflammation to address residual CV risk

3' education - Mar. 17, 2017 - Dr. Paul M. Ridker - Boston, MA, USA

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

3' education - Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

Targeting residual inflammatory risk as a strategy to lower CV risk

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)

Inflammation as potential target for therapy to target residual risk post ACS

10' education - Aug. 27, 2016 - ESC 2016, Rome - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Mechanisms involved in HFpEF and how they are or may be targeted for therapy

Literature - June 26, 2018 - Lam CSP et al., - Eur Heart J 2018

This review describes six mechanisms underlying HFpEF with potential translational significance; three haemodynamic mechanisms and cellular/molecular mechanisms.

Yogurt consumption before an unhealthy meal reduces postprandial inflammation

Literature - May 24, 2018 - Pei R, et al. - J Nutr 2018

Pre-meal yogurt consumption improved acute postprandial dysfunction after a high-fat, high-calorie meal in obese and non-obese women.

Cardiovascular Inflammation Reduction Trial (CIRT) stopped early

News - May 22, 2018

The CIRT trial evaluating low-dose methotrexate to lower CV risk has been stopped early, not based on any substantive safety concerns.

Inflammatory response is activated in end stage HF: a potential new therapeutic target?

News - Apr. 24, 2018

A small study found antibodies in plasma and heart muscle of end-stage heart failure patients, and more so if HF was caused by ischemic heart disease than by cardiomyopathy.

Elevated pro-inflammatory biomarkers associated with decompensation in HFpEF

Literature - Apr. 18, 2018 - Abernethy A et al. - J Am Heart Assoc. 2018
Levels of pro-inflammatory biomarkers were significantly elevated in decompensated compared with stable HF patients with preserved ejection fraction, and some were linked with altered diastolic function.

Levels of pro-inflammatory biomarkers were significantly elevated in decompensated compared with stable HF patients with preserved ejection fraction, and some were linked with altered diastolic function.

The CANTOS trial: Implications for the management of patients with residual risk

10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME
Prof. Paul Ridker discusses the insights that originate from the CANTOS trial, in which reducing inflammation with canakinumab reduced CV events. These findings have implications for the management of residual risk.

Prof. Paul Ridker discusses the insights that originate from the CANTOS trial, in which reducing inflammation with canakinumab reduced CV events. These findings have implications for the management of residual risk.

Fecal microbiota transplantation of vegan donor did not lower arterial wall inflammation

Literature - Apr. 3, 2018 - Smits LP et al. - J Am Heart Assoc. 2018

In a double-blind pilot study, a single lean vegan-donor fecal microbiota transplantation in obese male patients with metabolic syndrome did not alter markers of arterial wall inflammation.

CV benefit of PCSK9 inhibitor is consistent regardless of inflammation level

Literature - Mar. 13, 2018 - Bohula EA et al. - Circulation 2018
A prespecified FOURIER-analysis showed that evolocumab decreases CV events across hsCRP strata, with greater absolute risk reductions in patients with higher baseline hsCRP.

ACC 2018 A prespecified FOURIER-analysis showed that evolocumab decreases CV events across hsCRP strata, with greater absolute risk reductions in patients with higher baseline hsCRP.

No evidence that anti-inflammatory treatment prevents progression to T2DM in CANTOS trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Brendan Everett, MD - Boston, MA, USA
Due to the observed link between inflammation and aberrant insulin regulation, a key secondary outcomes of the CANTOS trial was new onset T2DM in patients with prediabetes at baseline.

ACC 2018 Due to the observed link between inflammation and aberrant insulin regulation, a key secondary outcomes of the CANTOS trial was new onset T2DM in patients with prediabetes at baseline.

Anti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Paul Ridker - Boston, MA, USA
A new analysis of the CANTOS trial showed that IL-1β inhibition with canakinumab in patients with stage 3 kidney disease did not slow progression to renal failure, but did beneficially alter outcomes in these very high risk patients.

ACC 2018 A new analysis of the CANTOS trial showed that IL-1β inhibition in patients with stage 3 kidney disease did not slow progression to renal failure, but did beneficially alter outcomes in these very high risk patients.

IL-1β inhibitor does not prevent new onset type 2 diabetes

Presented at ACC.18 by Brendan Everett (Boston, MA, USA)

News - Mar. 12, 2018

ACC 2018 In a sub-analysis of the CANTOS trial, canakinumab showed a similar CV event reduction in diabetics and non-diabetics, but did not prevent the progression from pre-diabetes to diabetes.

IL-1β inhibitor reduces major vascular events in patients with CKD

Presented at ACC.18 by Paul Ridker (Boston, MA, USA)

News - Mar. 11, 2018
Treatment with canakinumab reduced MACE+ in patients with CKD in the CANTOS trial, with a stronger reduction in those who achieved on-treatment hsCRP<2 mg/mL compared to >2 mg/mL.

ACC 2018 Treatment with canakinumab reduced MACE+ in patients with CKD in the CANTOS trial, with a stronger reduction in those who achieved on-treatment hsCRP<2 mg/mL compared to >2 mg/mL.